Kodiak Sciences (KOD) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 540.1% versus a loss of 11.4%. Over five years, RYTM leads with a +682.1% price change compared with -18.7% for KOD. Rhythm Pharmaceuticals is the larger company by market cap ($6.09 billion vs $5.72 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KOD | RYTM |
|---|---|---|
| Share price | $91.08 | $88.45 |
| Market cap | $5.72B | $6.09B |
| 1-day change | -1.36% | -2.56% |
| YTD return | +225.75% | -17.37% |
| 1-year return | +540.06% | -11.40% |
| 5-year return | -18.66% | +682.05% |
| EPS (TTM) | $-4.19 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $189.76M |
| Revenue growth (YoY) | — | +45.83% |
| Net income (latest FY) | $-229.97M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | — | -101.19% |
| Net margin | — | -103.57% |
| 52-week high | $104.00 | $122.20 |
| 52-week low | $10.94 | $74.50 |
| Distance from 52-week high | -12.42% | -27.62% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +28.10% | +56.69% |
| Average volume | 1.57M | 646.31K |
| Shares outstanding | 62.85M | 68.85M |
| Employees | 141 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed RYTM by 551.5 percentage points over the past year.
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
KOD vs RYTM FAQ
Which is bigger, Kodiak Sciences or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $6.09B compared with $5.72B for Kodiak Sciences (KOD).
Which stock has performed better over the past year, KOD or RYTM?
KOD returned +540.06% over the past 12 months, compared with -11.40% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Kodiak Sciences and Rhythm Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Kodiak Sciences and Biotechnology: Pharmaceutical Preparations for Rhythm Pharmaceuticals.